Bristol-Myers Squibb (BMY) Completes Tender Offer for Medarex (MEDX)
More News related to BMY
- Notable 52-Week High's and Low's: BMY, JCG, PBR, SLW, GOOG, INCY, NTAP, QADI, GOLD, BONT Higher; SPWRB Low
- Asterand Announces Extension of Agreement with Bristol-Myers Squibb
- U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)
- Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); Raises PT
- Trading Overview for Poniard Pharmaceuticals Inc. Issued by Beacon Equity
More News related to MEDX
- Bristol-Myers Squibb (BMY) Completes Acquisition of Medarex
- Bristol-Myers Squibb (BMY) Completes Tender Offer for Medarex (MEDX)
- Notable Mergers and Acquisitions of the Day 8/21: MNOV/AVGN, BMY/MEDX, ORCL/JAVA
- Bristol-Myers (BMY) Extends Tender Offer for Medarex (MEDX) to August 26
- Medarex (MEDX) Reports Solid Q2 Results
Bristol-Myers Squibb Company (NYSE: BMY) announced that the depositary for its tender offer for all the outstanding common stock of Medarex has advised that, as of the expiration of the subsequent offering period, shareholders of Medarex, Inc. (NASDAQ: MEDX) tendered approximately 120,417,467 shares, representing, together with the 2,879,223 shares of Medarex common stock owned by Bristol-Myers Squibb since January 2005, approximately 90.7% of the Medarex shares outstanding.
Related Categories
Corporate NewsMergers and Acquisitions
Stocks Mentioned
+0.49Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
